Dive Brief: Amicus Therapeutics on Friday won an accelerated U.S. approval of its Fabry disease drug Galafold, giving patients with the rare genetic disorder a new treatment option for the first time in over a decade. The Food and Drug Administration’s OK comes about one year after the agency dropped a requirement for further study of the drug, reversing...